weekly_bull3

The Week in Review: October 27, 2017 – November 4, 2017

Friday, November-4-17

News Recap

Canada not going to meet 2030 elimination target, MSF secures lower prices for generics, Vermont and NC Medicaid eliminate access restrictions,  hepatitis B virus core-related antigen (HBcrAg) levels associated with progression to cirrhosis, and more……..

Read more…http://hepcbc.ca/2017/11/03/week-review-october-27-november-4-2017/

red line

The Week in Review: October 20, 2017 – October 27, 2017

Friday, October-27-17

News Recap

Patient input requested for BC PharmaCare review of AbbVie’s combo of glecaprevir and pibrentasvir (GP) for Genotypes 1-6. Overview of AASLD 2017, the latest on DAAs and liver tranplant outcomes, and some news on the HBV front: Transgene’s TG1050 and other news……..

Read more…http://hepcbc.ca/2017/10/27/week-review-october-20-october-27-2017/

red line

The Week in Review: October 13, 2017 – October 20, 2017

Friday, October-20-17

News Recap

HCV and pregnancy, rheumatic disease and HCV, SVR and portal hypertension, steatosis and cannabis, rise in liver cancer rates, HAV epidemic in California, ……..

Read more…http://hepcbc.ca/2017/10/20/week-review-october-13-october-20-2017/

red line

The Week in Review: October 6, 2017 – October 13, 2017

Friday, October-13-17

News Recap

How HCV hides in the body; a new blood test to find liver cancer; rapid fibrosis in co-infected MSM, inadequate hospice care for people with chronic liver disease, efficacy of Maviret in chronic kidney disease ……..

Read more…http://hepcbc.ca/2017/10/13/week-review-october-6-october-13-2017/

red line

2017

September Archive:

August Archive:

July Archive:

June Archive:

May Archive:

April Archive:

March Archive:

February Archive:

January Archive:

 

2016

December Archive:

November Archive:

October Archive:

September Archive: